Boston Scientific has announced that the Platinum China study, which was presented at China Interventional Therapeutics (20–23 March, Beijing, China), indicated that the Promus Element stent is associated with a low rate of stent thrombosis at nine months. These data support the existing safety and efficacy data for the stent.
According to a company press release, the Platinum China study—a separate arm of the overall Platinum trial programme—demonstrated a low nine-month ARC definite/probable stent thrombosis rate of 0% and a 2.2% nine-month target lesion revascularisation rate with the Promus Element stent.
The principal investigator of the trial is Gao Runlin from Fuwai Hospital, National Center for Cardiovascular Disease of China, and a member of the Chinese Academy of Engineering, and Han Yaling, a renowned cardiovascular expert from Shenyang Northern General Hospital, was the co-lead researcher and co-principal investigator.
Michael F. Mahoney, chief executive officer of Boston Scientific, said: “As an innovative global leader in the field of coronary intervention, Boston Scientific is dedicated to providing a wide range of high-quality and efficient solutions for customers and patients in China.”
